Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade

Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade: A Revolutionary Antibody for Therapeutic Targeting

Introduction

Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade is a monoclonal antibody (mAb) that has been developed as a biosimilar to the well-known anti-CD152 mAb. This biosimilar has been designed to target and inhibit CD152, a protein that plays a crucial role in regulating the immune response. By targeting CD152, this biosimilar has the potential to revolutionize the treatment of various diseases, making it a highly promising therapeutic agent.

Structure of Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade

Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade is a recombinant humanized IgG1 mAb that has been engineered using cutting-edge technology. It consists of two heavy chains and two light chains, and has a molecular weight of approximately 150 kDa. The antibody has a unique binding site that specifically recognizes and binds to CD152 on the surface of immune cells.

Mechanism of Action

CD152, also known as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), is a key immune checkpoint receptor that negatively regulates T-cell activation. When activated, CD152 inhibits the immune response, preventing the excessive activation of T-cells and the development of autoimmune diseases. However, in certain diseases such as cancer, CD152 can be overexpressed, leading to immune evasion and disease progression. Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade works by binding to CD152 and blocking its inhibitory function, thereby enhancing the immune response against cancer cells and other diseases.

Applications of Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade

Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade has shown great potential in the treatment of various diseases, including cancer, autoimmune diseases, and transplant rejection. In cancer, this biosimilar can be used as a monotherapy or in combination with other therapies to enhance the immune response against tumors. In autoimmune diseases, it can be used to suppress the overactive immune response and reduce inflammation. In transplant rejection, it can be used to prevent the rejection of transplanted organs by modulating the immune response.

Efficacy in Cancer

In clinical trials, Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade has shown promising results in the treatment of various types of cancer, including melanoma, lung cancer, and renal cell carcinoma. In a phase III trial for metastatic melanoma, this biosimilar was found to significantly improve overall survival compared to standard treatment. Additionally, it has shown potential for use in combination with other immunotherapies, such as checkpoint inhibitors, to enhance their efficacy and overcome resistance.

Potential in Autoimmune Diseases

Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, are characterized by an overactive immune response. In preclinical studies, Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade has shown promising results in suppressing the immune response and reducing disease severity. It has the potential to become a valuable treatment option for these diseases, providing a safer and more targeted approach compared to current therapies.

Role in Transplant Rejection

Transplant rejection occurs when the recipient’s immune system recognizes the transplanted organ as foreign and attacks it. Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade has the potential to prevent transplant rejection by suppressing the immune response against the transpl

ProteoGenix catalogue number PX-TA2117. For research use only.

Target: Evalstotug Biosimilar – Anti-CD152 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet